Isodiol International Incorporated is a Canada-based life science company specializing in the development, production and commercialization of hemp-derived cannabidiol (CBD) ingredients and finished products. The company operates a vertically integrated platform that spans plant cultivation, advanced extraction technologies and product formulation. Isodiol serves a diverse range of end markets, including pharmaceuticals, nutraceuticals, cosmetics and consumer packaged goods.
Central to Isodiol’s offering is its portfolio of patented and proprietary delivery technologies designed to improve the solubility, bioavailability and stability of CBD. Products include water-soluble powders, oil-based concentrates, MCT-encapsulated oils, gels, gummies and topical formulations. The company also provides contract development and manufacturing services (CDMO) to global brands seeking turnkey solutions from early-stage formulation through to commercial-scale production and packaging.
With headquarters in Vancouver, British Columbia, Isodiol maintains Good Manufacturing Practice (GMP) and ISO-certified facilities that support international distribution. The company’s footprint spans North America, Europe, Asia and Australia, with partnerships and sales channels targeting both regulated and emerging markets. Supply chain transparency, quality assurance and regulatory compliance are pillars of Isodiol’s operations, backed by third-party testing and traceability protocols.
Founded in 2018, Isodiol is led by an executive team with deep expertise in biotechnology, pharmaceutical development and global distribution. Under their guidance, the company has pursued strategic collaborations with research institutions and industry leaders to advance new applications of CBD in health and wellness. Isodiol continues to expand its intellectual property portfolio and manufacturing capacity to meet growing demand across multiple sectors.
AI Generated. May Contain Errors.
